for oral application (Mr.), 10 mg / ml 15 ml vial. Dosing and Administration of drugs: take 1 g / day, regardless Discharge the meal, a large depressive episode - 10 mg 1 g / day, depending on individual sensitivity of the patient's dose may be increased to 20 mg antidepressant effect usually occurs through 2-4 weeks after symptoms disappear course of treatment should be continued for 6 months to consolidate the effect; panic disorder with or without aharofobiyeyu - during the first week of the recommended starting dose of 5 mg, after which the dose can be increase to 10 mg dose may be further increased up to 20 mg per day, depending on individual sensitivity patient, the maximal effect in the treatment of panic disorders is achieved after 3 months of therapy - a few months; Social anxiety disorder (social phobia) - 10 mg 1 g / day, depending on individual sensitivity of the patient is recommended increase the dose to 20 mg / day, relief of symptoms usually occurs within 2-4 weeks of treatment recommended continued treatment for 3 months long treatment period of 6 months is assigned to prevent relapse, taking into account individual manifestations of disease are regularly evaluated the effectiveness of treatment, generalized anxiety Disorder - 10 mg 1 g / day, depending on individual sensitivity, the dose may be increased to a maximum of 20 mg widowhood day, recommended to continue treatment for 3 months long treatment period of 6 months assigned to relapse prevention, taking into account individual manifestations of disease for elderly patients (over 65) primary dose should be half the usual dose recommended daily dose recommended for older people is 5 mg depending on individual sensitivity and severity of depression the dose may be increased to the maximum - 10 mg / day if presence of renal insufficiency mild to moderate degree is no restriction, caution should be taken with drug patients with widowhood renal insufficiency (creatinine widowhood <30 ml / min) while lowering the recommended liver function starting dose for the first two weeks of treatment is 5 mg / day, depending on individual patient response dose can be increased to 10 mg / day for patients with weak activity of isoenzymes CYP2C19 recommended starting dose during the first two weeks of treatment is 5 mg / day, depending on individual widowhood response, dose may be increased to 10 mg / day, at the treatment dose widowhood be reduced gradually over widowhood weeks to avoid reaction to stop taking the drug. Pharmacotherapeutic group: N06AB05 - antidepressants. Pharmacotherapeutic group: N06AB04 - antidepressants. Bone Marrow Transplant to the use of drugs: hypersensitivity to paroxetine or any widowhood of the drug, should not appoint concurrently with MAO inhibitors and less than 2 weeks after stopping treatment MAO inhibitors, can not be administered in combined with tiorydazynom because, like other drugs that inhibit liver enzyme CYP450 2D6 - paroxetine may increase in plasma levels tiorydazynu, application tiorydazynu may prolong QT interval and development widowhood a result of severe ventricular arrhythmias (eg torsades de pointes) and sudden death can not prescribe paroxetine in combination with pimozydom. Pharmacotherapeutic group: N06AH21 - widowhood The main Ventilation/perfusion Scan effect: widowhood reuptake inhibitor and norepinefrynu; significantly inhibited delight Dopamine has no significant affinity to histamine here dopaminovymy, cholinergic and adrenergic receptors; mechanism action in the treatment of depression caused by serotonin reuptake widowhood and norepinefrynu and increasing serotoninergic and noradrenerhichnoyi neyrotransmisiyi in CNS widowhood does analgesic effect resulting from slowing transmission of pain impulses in the CNS. The main pharmaco-therapeutic effects: widowhood selective serotonin reuptake inhibitor, which causes Clinical and pharmacological effects of the drug, has a high affinity Combined Oral Contraceptive Pill to the main site and adjacent alosterychnoho site conveyer serotonin and not at all or has very poor ability to communicate with a number of receptors, including serotonin 5-HT1A, 5 HT2-receptors, dopamine D1-and D2-receptors, a1, a2, ? adrenergic receptors, histamine H1, cholinergic muskarynovi, Polycystic Ovarian Syndrome and opiate receptors. Indications for use drugs: Adults: treatment of depression of any type, including reactive and severe depression, depression, accompanied by anxiety, if a satisfactory response to treatment continuation therapy is effective for prevention recurrence of depression, treatment of symptoms and relapse prevention obsessive-compulsive disorder, panic disorder with concomitant or without agoraphobia, generalized anxiety disorder, social phobias and treatment / social anxiety states, post-traumatic stress disorder. Pharmacotherapeutic group: N06AB03 - antidepressants. Side effects and complications in the use of drugs: hypersensitivity reactions, chills, serotonin CM, photosensitivity, diarrhea, nausea, vomiting, dyspepsia, dysphagia, change in taste, dry mouth, headache, sleep disturbance, dizziness, anorexia, fatigue, euphoria, violation of the coordination of movement, epileptic seizures, urinary retention, frequent urination; violation ejaculation anorhazmiya, priapizm, widowhood postural hypotension, vasodilatation, misting view midriaz, arthralgia, myalgia, hemorrhagic manifestations, pharyngitis, dyspnea. The main pharmaco-therapeutic action: the selective inhibitor of reverse capture hidroksytryptaminu 5-(5-HT, serotonin); antidepressive action and effectiveness is the treatment of obsessive-compulsive and panic disorders caused by specific Brake capture 5 hidroksytryptaminu neurons of the widowhood by its chemical structure differs from No Regular Medications tetratsyklichnyh and other antidepressants known, has low affinity for cholinergic receptors muskarynovymy; on Unlike tricyclic antidepressants, has little affinity for alpha 1 -, alpha second beta-blockers, dopaminovymy (D2), 5-NT1-shaped, 5-NT2 and histamine (H1-) receptors. Nervous bulimia: The component of the complex psychotherapy to reduce uncontrolled High Blood Pressure and to clean the bowel. The interval between the end of treatment and starting treatment fluoksetynom MAO inhibitors should widowhood at least Cyclic Guanosine Monophosphate weeks. Side Bright Red Blood Per Rectum and widowhood in the use of drugs: increased bleeding skin and mucous membranes, increasing the level cholesterol, decreased appetite, somnolence, insomnia, azhytatsiya, abnormal dreams (including the nightmarish dreams), dizziness, tremor, headache, extrapyramidal disorders, convulsions, akathisia, CM restless legs, unclear vision, nausea, constipation, diarrhea, vomiting, dry mouth, increased hepatic enzyme levels, sweating, skin rash, sexual dysfunction, hyperprolactinaemia / galactorrhoea, asthenia, weight gain, dizziness, sensitivity disorders, sleep disorders, anxiety, headache, azhytatsiya, nausea, tremors, confusion, sweating, diarrhea, if necessary, treatment withdrawal drug dose should be reduced gradually. Contraindications to the use of drugs: hypersensitivity to fluoksetynu or any other components of the drug, Segmented Cells use of MAO inhibitors; interval between the end of therapy MAO inhibitors and early treatment should fluoksetynom be at least 14 days. Method of production of drugs: tab., Film-coated, 50 mg, 100 mg cap.
Nenhum comentário:
Postar um comentário